氢吗啡酮 (Chinese Wikipedia)

Analysis of information sources in references of the Wikipedia article "氢吗啡酮" in Chinese language version.

refsWebsite

Global rank Chinese rank

13nih.gov

4^th place

5^th place

12doi.org

2^nd place

23^rd place

11web.archive.org

1^st place

5books.google.com

3^rd place

8^th place

4drugs.com

399^th place

208^th place

4semanticscholar.org

11^th place

332^nd place

2clincalc.com

3,912^th place

5,917^th place

2rxlist.com

7,927^th place

5,088^th place

2fda.gov

447^th place

581^st place

1psu.edu

207^th place

628^th place

1in.gov.br

3,151^st place

low place

1handle.net

102^nd place

492^nd place

1purduepharma.com

low place

1rapiddrugdetox.com

low place

1acadianaaddiction.com

low place

1narconon.org

low place

1worldcat.org

5^th place

12^th place

1alfredhealth.org.au

low place

1mcmaster.ca

6,572^nd place

low place

1thatspoppycock.com

low place

1virginia.edu

1,041^st place

1,913^th place

1harvard.edu

18^th place

57^th place

1nps.org.au

low place

1usdoj.gov

2,755^th place

3,156^th place

1ohio.gov

5,298^th place

low place

1bbc.co.uk

8^th place

32^nd place

acadianaaddiction.com

Dilaudid Abuse & Addiction Withdrawals, Signs, Symptoms & Effects – Acadiana Addiction Center. www.acadianaaddiction.com. [2015-11-05].

alfredhealth.org.au

Opioid Conversion Guidelines (PDF). alfredhealth.org.au. [2017-09-02]. （原始内容 (PDF)存档于2016-03-04）. 已忽略未知参数|df= (帮助)

bbc.co.uk

Arizona execution takes two hours. BBC News. 2014-07-24 [2014-07-24].

books.google.com

Bonewit-West K, Hunt SA, Applegate E. Today's Medical Assistant: Clinical and Administrative Procedures. Elsevier Health Sciences. 2012: 571. ISBN 9781455701506.
Bonewit-West K, Hunt SA, Applegate E. Today's Medical Assistant: Clinical and Administrative Procedures. Elsevier Health Sciences. 2012: 571 [2019-08-20]. ISBN 9781455701506. （原始内容存档于2023-01-10）.
Polsten GR, Wallace MS. Analgesic Agents in Rheumatic Disease. Firestein GS, Budd R, Gabriel SE, McInnes IB, O'Dell JR (编). Kelley and Firestein's Textbook of Rheumatology. Elsevier Health Sciences. 2016-06-21: 1081–. ISBN 978-0-323-41494-4.
Fischer J, Ganellin CR. Analogue-based Drug Discovery. John Wiley & Sons. 2006: 526. ISBN 9783527607495.
Vardanyan R, Hruby V. Synthesis of Essential Drugs. Elsevier. 2006: 25. ISBN 9780080462127.

clincalc.com

The Top 300 of 2022. ClinCalc. [2024-08-30]. （原始内容存档于2024-08-30）.
Hydromorphone Drug Usage Statistics, United States, 2013 - 2022. ClinCalc. [2024 -08-30].

doi.org

Coda BA, Rudy AC, Archer SM, Wermeling DP. Pharmacokinetics and bioavailability of single-dose intranasal hydromorphone hydrochloride in healthy volunteers. Anesthesia and Analgesia. July 2003, 97 (1): 117–23, table of contents. CiteSeerX 10.1.1.551.6509 . PMID 12818953. S2CID 22694749. doi:10.1213/01.ANE.0000066311.40978.4F.
Vallner JJ, Stewart JT, Kotzan JA, Kirsten EB, Honigberg IL. Pharmacokinetics and bioavailability of hydromorphone following intravenous and oral administration to human subjects. Journal of Clinical Pharmacology. April 1981, 21 (4): 152–156. PMID 6165742. S2CID 29864565. doi:10.1002/j.1552-4604.1981.tb05693.x.
Li Y, Ma J, Lu G, Dou Z, Knaggs R, Xia J, Zhao S, Dong S, Yang L. Hydromorphone for cancer pain. The Cochrane Database of Systematic Reviews. August 2021, 2021 (8): CD011108. PMC 8406835 . PMID 34350974. doi:10.1002/14651858.CD011108.pub3.
Brennan MJ. The effect of opioid therapy on endocrine function. The American Journal of Medicine. March 2013, 126 (3 Suppl 1): S12–S18. PMID 23414717. doi:10.1016/j.amjmed.2012.12.001.
Thwaites D, McCann S, Broderick P. Hydromorphone neuroexcitation. Journal of Palliative Medicine. August 2004, 7 (4): 545–550. PMID 15353098. doi:10.1089/1096621041838362.
Gagnon DJ, Jwo K. Tremors and agitation following low-dose intravenous hydromorphone administration in a patient with kidney dysfunction. The Annals of Pharmacotherapy. 2013, 47 (7–8): e34. PMID 23715067. S2CID 21782204. doi:10.1345/aph.1R784.
Rapp SE, Egan KJ, Ross BK, Wild LM, Terman GW, Ching JM. A multidimensional comparison of morphine and hydromorphone patient-controlled analgesia. Anesthesia and Analgesia. May 1996, 82 (5): 1043–1048. PMID 8610865. doi:10.1213/00000539-199605000-00029 .
Sarhill N, Walsh D, Nelson KA. Hydromorphone: pharmacology and clinical applications in cancer patients. Supportive Care in Cancer. March 2001, 9 (2): 84–96. PMID 11305075. S2CID 22849970. doi:10.1007/s005200000183.
Smith A, Gomez-Panzani E, Mills S, Rainey G, Tolia G, Tagliaferri F, Spratlin V. (807) 24-hour transdermal delivery of hydromorphone hydrochloride. The Journal of Pain (Clinical trial abstract). 2006, 7 (4): S52. ISSN 1526-5900. doi:10.1016/j.jpain.2006.01.209 .
Gregory TB. Hydromorphone: evolving to meet the challenges of today's health care environment. Clinical Therapeutics. December 2013, 35 (12): 2007–2027. PMID 24290733. doi:10.1016/j.clinthera.2013.09.027.
Long MT, Hailes AM, Kirby GW, Bruce NC. Transformations of morphine alkaloids by Pseudomonas putida M10. Applied and Environmental Microbiology. October 1995, 61 (10): 3645–3649. Bibcode:1995ApEnM..61.3645L. PMC 167664 . PMID 7487001. doi:10.1128/AEM.61.10.3645-3649.1995.
Felden L, Walter C, Harder S, Treede RD, Kayser H, Drover D, Geisslinger G, Lötsch J. Comparative clinical effects of hydromorphone and morphine: a meta-analysis. British Journal of Anaesthesia. September 2011, 107 (3): 319–328. PMID 21841049. doi:10.1093/bja/aer232 .

drugs.com

Hydromorphone Use During Pregnancy. Drugs.com. 2019-11-19 [2020-05-16].
Hydromorphone Hydrochloride Monograph for Professionals. Drugs.com. American Society of Health-System Pharmacists. [15 April 2019].
Hydromorphone Use During Pregnancy. Drugs.com. [2019-04-15].
Drug interactions between Dilaudid and Valium. [2014 -11-19].

fda.gov

accessdata.fda.gov

DILAUDID® ORAL LIQUID and DILAUDID® TABLETS Package Insert (PDF). FDA. 2007 [2015-11-05].

fda.gov

Information for Healthcare Professionals: Hydromorphone Hydrochloride Extended-Release Capsules (marketed as Palladone). Center for Drug Evaluation and Research. 2005-07-15 [2016-08-16].

handle.net

hdl.handle.net

World Health Organization. The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. 2023. hdl:10665/371090 . WHO/MHP/HPS/EML/2023.02.

harvard.edu

ui.adsabs.harvard.edu

Long MT, Hailes AM, Kirby GW, Bruce NC. Transformations of morphine alkaloids by Pseudomonas putida M10. Applied and Environmental Microbiology. October 1995, 61 (10): 3645–3649. Bibcode:1995ApEnM..61.3645L. PMC 167664 . PMID 7487001. doi:10.1128/AEM.61.10.3645-3649.1995.

in.gov.br

Anvisa. RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control]. Diário Oficial da União. 2023-03-31 (2023-04-04) [2023-08-16]. （原始内容存档于2023-08-03）（巴西葡萄牙语）.

mcmaster.ca

nationalpaincentre.mcmaster.ca

Switching Opioids (PDF). mcmaster.ca. [2017-09-02].

narconon.org

Hydromorphone Drug Information. Narconon International. [2015-11-05].

nih.gov

ncbi.nlm.nih.gov

Coda BA, Rudy AC, Archer SM, Wermeling DP. Pharmacokinetics and bioavailability of single-dose intranasal hydromorphone hydrochloride in healthy volunteers. Anesthesia and Analgesia. July 2003, 97 (1): 117–23, table of contents. CiteSeerX 10.1.1.551.6509 . PMID 12818953. S2CID 22694749. doi:10.1213/01.ANE.0000066311.40978.4F.
Vallner JJ, Stewart JT, Kotzan JA, Kirsten EB, Honigberg IL. Pharmacokinetics and bioavailability of hydromorphone following intravenous and oral administration to human subjects. Journal of Clinical Pharmacology. April 1981, 21 (4): 152–156. PMID 6165742. S2CID 29864565. doi:10.1002/j.1552-4604.1981.tb05693.x.
Li Y, Ma J, Lu G, Dou Z, Knaggs R, Xia J, Zhao S, Dong S, Yang L. Hydromorphone for cancer pain. The Cochrane Database of Systematic Reviews. August 2021, 2021 (8): CD011108. PMC 8406835 . PMID 34350974. doi:10.1002/14651858.CD011108.pub3.
Brennan MJ. The effect of opioid therapy on endocrine function. The American Journal of Medicine. March 2013, 126 (3 Suppl 1): S12–S18. PMID 23414717. doi:10.1016/j.amjmed.2012.12.001.
Thwaites D, McCann S, Broderick P. Hydromorphone neuroexcitation. Journal of Palliative Medicine. August 2004, 7 (4): 545–550. PMID 15353098. doi:10.1089/1096621041838362.
Gagnon DJ, Jwo K. Tremors and agitation following low-dose intravenous hydromorphone administration in a patient with kidney dysfunction. The Annals of Pharmacotherapy. 2013, 47 (7–8): e34. PMID 23715067. S2CID 21782204. doi:10.1345/aph.1R784.
Rapp SE, Egan KJ, Ross BK, Wild LM, Terman GW, Ching JM. A multidimensional comparison of morphine and hydromorphone patient-controlled analgesia. Anesthesia and Analgesia. May 1996, 82 (5): 1043–1048. PMID 8610865. doi:10.1213/00000539-199605000-00029 .
Bell CC. Simultaneous treatment of hypertension and opiate withdrawal using an alpha 2-adrenergic agonist. Journal of the National Medical Association. January 1983, 75 (1): 89–93. PMC 2561435 . PMID 6131140.
Nersesyan H, Slavin KV. Current approach to cancer pain management: Availability and implications of different treatment options. Therapeutics and Clinical Risk Management. June 2007, 3 (3): 381–400. PMC 2386360 . PMID 18488078.
Sarhill N, Walsh D, Nelson KA. Hydromorphone: pharmacology and clinical applications in cancer patients. Supportive Care in Cancer. March 2001, 9 (2): 84–96. PMID 11305075. S2CID 22849970. doi:10.1007/s005200000183.
Gregory TB. Hydromorphone: evolving to meet the challenges of today's health care environment. Clinical Therapeutics. December 2013, 35 (12): 2007–2027. PMID 24290733. doi:10.1016/j.clinthera.2013.09.027.
Long MT, Hailes AM, Kirby GW, Bruce NC. Transformations of morphine alkaloids by Pseudomonas putida M10. Applied and Environmental Microbiology. October 1995, 61 (10): 3645–3649. Bibcode:1995ApEnM..61.3645L. PMC 167664 . PMID 7487001. doi:10.1128/AEM.61.10.3645-3649.1995.
Felden L, Walter C, Harder S, Treede RD, Kayser H, Drover D, Geisslinger G, Lötsch J. Comparative clinical effects of hydromorphone and morphine: a meta-analysis. British Journal of Anaesthesia. September 2011, 107 (3): 319–328. PMID 21841049. doi:10.1093/bja/aer232 .

nps.org.au

Hydromorphone prolonged-release tablets (Jurnista) for chronic severe disabling pain. NPS Medicinewise. May 2009 [2020-12-07].

ohio.gov

drc.ohio.gov

Ohio Prisons Director Announces Changes to Ohio's Execution Process. Ohio Department of Rehabilitation and Correction. 2009-11-13 [2014-01-17]. （原始内容存档于2013-01-15）. 已忽略未知参数|df= (帮助)

psu.edu

citeseerx.ist.psu.edu

Coda BA, Rudy AC, Archer SM, Wermeling DP. Pharmacokinetics and bioavailability of single-dose intranasal hydromorphone hydrochloride in healthy volunteers. Anesthesia and Analgesia. July 2003, 97 (1): 117–23, table of contents. CiteSeerX 10.1.1.551.6509 . PMID 12818953. S2CID 22694749. doi:10.1213/01.ANE.0000066311.40978.4F.

purduepharma.com

app.purduepharma.com

Dilaudid (hydromorphone hydrochloride) Oral LiquidDilaudid (hydromorphone hydrochloride) Tablets. app.purduepharma.com. [2015-11-05]. （原始内容存档于2016-03-04）.

rapiddrugdetox.com

Hydromorphone / Dilaudid Detox. Rapid Drug Detox. [2015-11-05].

rxlist.com

Hydromorphone Monograph (Side Effects & Drug Interactions). RxList Inc. 2008. （原始内容存档于2008-02-13）.
Dilaudid Clinical Pharmacology. rxlist.com. [2017-09-02]. （原始内容存档于2008-06-12）. 已忽略未知参数|df= (帮助)

semanticscholar.org

api.semanticscholar.org

Coda BA, Rudy AC, Archer SM, Wermeling DP. Pharmacokinetics and bioavailability of single-dose intranasal hydromorphone hydrochloride in healthy volunteers. Anesthesia and Analgesia. July 2003, 97 (1): 117–23, table of contents. CiteSeerX 10.1.1.551.6509 . PMID 12818953. S2CID 22694749. doi:10.1213/01.ANE.0000066311.40978.4F.
Vallner JJ, Stewart JT, Kotzan JA, Kirsten EB, Honigberg IL. Pharmacokinetics and bioavailability of hydromorphone following intravenous and oral administration to human subjects. Journal of Clinical Pharmacology. April 1981, 21 (4): 152–156. PMID 6165742. S2CID 29864565. doi:10.1002/j.1552-4604.1981.tb05693.x.
Gagnon DJ, Jwo K. Tremors and agitation following low-dose intravenous hydromorphone administration in a patient with kidney dysfunction. The Annals of Pharmacotherapy. 2013, 47 (7–8): e34. PMID 23715067. S2CID 21782204. doi:10.1345/aph.1R784.
Sarhill N, Walsh D, Nelson KA. Hydromorphone: pharmacology and clinical applications in cancer patients. Supportive Care in Cancer. March 2001, 9 (2): 84–96. PMID 11305075. S2CID 22849970. doi:10.1007/s005200000183.

thatspoppycock.com

Hydromorphone. That's Poppycock!. 2009-02-19 [5 November 2012]. （原始内容存档于2012-10-14）.

usdoj.gov

deadiversion.usdoj.gov

Proposed Adjustments to the Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2013. Drug Enforcement Administration (DEA), Department of Justice. 2014-06-20 [2014-07-06]. （原始内容存档于2017-05-14）.

virginia.edu

medicine.virginia.edu

Buck M. Use of Hydromorphone in Children and Adolescents (PDF). University of Virginia Children's Hospital. July 2008 [2015-11-05]. （原始内容 (PDF)存档于2014-02-17）.

web.archive.org

Bonewit-West K, Hunt SA, Applegate E. Today's Medical Assistant: Clinical and Administrative Procedures. Elsevier Health Sciences. 2012: 571 [2019-08-20]. ISBN 9781455701506. （原始内容存档于2023-01-10）.
Anvisa. RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control]. Diário Oficial da União. 2023-03-31 (2023-04-04) [2023-08-16]. （原始内容存档于2023-08-03）（巴西葡萄牙语）.
The Top 300 of 2022. ClinCalc. [2024-08-30]. （原始内容存档于2024-08-30）.
Hydromorphone Monograph (Side Effects & Drug Interactions). RxList Inc. 2008. （原始内容存档于2008-02-13）.
Dilaudid (hydromorphone hydrochloride) Oral LiquidDilaudid (hydromorphone hydrochloride) Tablets. app.purduepharma.com. [2015-11-05]. （原始内容存档于2016-03-04）.
Opioid Conversion Guidelines (PDF). alfredhealth.org.au. [2017-09-02]. （原始内容 (PDF)存档于2016-03-04）. 已忽略未知参数|df= (帮助)
Hydromorphone. That's Poppycock!. 2009-02-19 [5 November 2012]. （原始内容存档于2012-10-14）.
Dilaudid Clinical Pharmacology. rxlist.com. [2017-09-02]. （原始内容存档于2008-06-12）. 已忽略未知参数|df= (帮助)
Buck M. Use of Hydromorphone in Children and Adolescents (PDF). University of Virginia Children's Hospital. July 2008 [2015-11-05]. （原始内容 (PDF)存档于2014-02-17）.
Proposed Adjustments to the Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2013. Drug Enforcement Administration (DEA), Department of Justice. 2014-06-20 [2014-07-06]. （原始内容存档于2017-05-14）.
Ohio Prisons Director Announces Changes to Ohio's Execution Process. Ohio Department of Rehabilitation and Correction. 2009-11-13 [2014-01-17]. （原始内容存档于2013-01-15）. 已忽略未知参数|df= (帮助)

worldcat.org

Smith A, Gomez-Panzani E, Mills S, Rainey G, Tolia G, Tagliaferri F, Spratlin V. (807) 24-hour transdermal delivery of hydromorphone hydrochloride. The Journal of Pain (Clinical trial abstract). 2006, 7 (4): S52. ISSN 1526-5900. doi:10.1016/j.jpain.2006.01.209 .